As clinical trials evaluating the safety and efficacy of rAAV-based gene augmentation therapy in CNGA3 achromatopsia patients are ongoing, the study presented here may have implications for these trials as well as for other ocular gene augmentation therapy trials utilizing rAAV. The gene discussed is CNGA3; the disease is achromatopsia.